Telo Historical Cash Flow
| TELO Stock | CAD 0.11 0.01 8.33% |
Analysis of Telo Genomics cash flow over time is an excellent tool to project Telo Genomics Corp future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as End Period Cash Flow of 3.2 M or Depreciation of 53.5 K as it is a great indicator of Telo Genomics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Telo Genomics Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Telo Genomics Corp is a good buy for the upcoming year.
Telo |
About Telo Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Telo balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Telo's non-liquid assets can be easily converted into cash.
Telo Genomics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Telo Genomics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Telo Genomics Corp current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telo Genomics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. At this time, Telo Genomics' Stock Based Compensation is fairly stable compared to the past year. Begin Period Cash Flow is likely to climb to about 3.3 M in 2024, whereas Free Cash Flow is likely to drop (2.6 M) in 2024.
Telo Genomics cash flow statement Correlations
Click cells to compare fundamentals
Telo Genomics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Telo Genomics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 901.5K | 2.7M | (943.5K) | (19.7K) | (22.7K) | (21.5K) | |
| Stock Based Compensation | 359.5K | 141.6K | 151.4K | 160.2K | 144.2K | 228.5K | |
| Free Cash Flow | (1.1M) | (1.1M) | (1.8M) | (2.7M) | (2.4M) | (2.6M) | |
| Change In Working Capital | (206.4K) | (51.1K) | 107.1K | (2.1K) | (2.4K) | (2.3K) | |
| Begin Period Cash Flow | 19.5K | 921.0K | 3.6M | 2.7M | 3.1M | 3.3M | |
| Other Cashflows From Financing Activities | 644.2K | 1.8M | 681.6K | (147.5K) | (169.6K) | (161.1K) | |
| Total Cash From Operating Activities | (1.1M) | (1.1M) | (1.8M) | (2.6M) | (2.4M) | (2.5M) | |
| Net Income | (1.2M) | (1.1M) | (2.1M) | (2.8M) | (2.5M) | (2.7M) | |
| Total Cash From Financing Activities | 2.0M | 3.8M | 876.6K | 2.7M | 3.1M | 2.4M | |
| End Period Cash Flow | 921.0K | 3.6M | 2.7M | 2.7M | 3.1M | 3.2M | |
| Depreciation | 64.7K | 62.2K | 57.0K | 33.1K | 29.8K | 53.5K | |
| Change To Account Receivables | (12.7K) | (47.5K) | 58.8K | (25.8K) | (29.7K) | (28.2K) | |
| Change To Operating Activities | 32.2K | (40.2K) | 39.5K | (28.1K) | (32.3K) | (30.7K) | |
| Change To Netincome | 343.4K | 263.8K | (45.7K) | 151.4K | 136.3K | 129.5K | |
| Change To Liabilities | 284.0K | (153.5K) | (43.2K) | 76.4K | 68.8K | 76.3K | |
| Investments | (8.7K) | (9.3K) | (25.2K) | (69.1K) | (79.4K) | (83.4K) | |
| Other Non Cash Items | (95.7K) | (183.5K) | 206.6K | 252.2K | 227.0K | 274.4K | |
| Issuance Of Capital Stock | 1.7M | 2.1M | 195K | 2.8M | 3.3M | 3.4M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Telo Stock Analysis
When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.